Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: ​ Data From 11 Trials With Over 3000 Patient-Years of Exposure. J of Skin 2025, 9 (1), s511. https://doi.org/10.25251/skin.9.supp.511.